An observational, retrospective, UK and Ireland audit of patient adherence to subcutaneous interferon beta-1a injections using the RebiSmart^® injection device

References

• CompstonAColesAMultiple sclerosisLancet200837296481502151718970977
   PubMed Web of Science ®Google Scholar
• IFNB Multiple Sclerosis Study GroupInterferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study GroupNeurology19934346556618469318
   PubMed Web of Science ®Google Scholar
• JacobsLDCookfairDLRudickRAIntramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)Ann Neurol19963932852948602746
   PubMed Web of Science ®Google Scholar
• JohnsonKPBrooksBRCohenJACopolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study GroupNeurology1995457126812767617181
   PubMed Web of Science ®Google Scholar
• PRISMS Study GroupRandomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study GroupLancet19983529139149815049820297
   PubMed Web of Science ®Google Scholar
• KapposLTraboulseeAConstantinescuCLong-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MSNeurology200667694495317000959
   PubMed Web of Science ®Google Scholar
• PRISMS Study Group and the University of British Columbia MS/MRI Analysis GroupPRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MSNeurology200156121628163611425926
   PubMed Web of Science ®Google Scholar
• Association of British NeurologistsRevised (2009) Association of British Neurologists’ guidelines for prescribing in multiple sclerosis Available from: http://www.abn.org.uk/abn/userfiles/file/ABN_MS_Guidelines_2009_Final(1).pdfAccessed March 11, 2013
   Google Scholar
• TrojanoMPellegriniFPaolicelliDItalian Multiple Sclerosis Database Network (MSDN) GroupReal-life impact of early interferon beta therapy in relapsing multiple sclerosisAnn Neurol200966451352019847899
   PubMed Web of Science ®Google Scholar
• Al-SabbaghABennetRKozmaCDicksonMMeleticheDMedication gaps in disease-modifying therapy for multiple sclerosis are associated with an increased risk of relapse: findings from a national managed care databaseJ Neurol2008255Suppl 2S79
   Google Scholar
• SteinbergSCFarisRJChangCFChanATankersleyMAImpact of adherence to interferons in the treatment of multiple sclerosis: a non-experimental, retrospective, cohort studyClin Drug Investig2013289100
   Web of Science ®Google Scholar
• DevonshireVLapierreYMacdonellRGAP Study GroupThe Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosisEur J Neurol2011181697720561039
   PubMed Web of Science ®Google Scholar
• PortaccioEZipoliVSiracusaGSorbiSAmatoMPLong-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosisEur Neurol2008593–413113518057899
   PubMed Web of Science ®Google Scholar
• LugaresiAAddressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?Expert Opin Drug Deliv200969995100219637982
   PubMed Web of Science ®Google Scholar
• DevonshireVAVerdun di CantognoEReview of subcutaneous interferon β-1a, delivered via the electronic self-injection device RebiSmart™, for the treatment of multiple sclerosisTher Deliv20112111455146522844681
   PubMedGoogle Scholar
• ExellSVerdunEDriebergenRA new electronic device for subcutaneous injection of IFN-β-1aExpert Rev Med Devices20118554355321728909
   PubMed Web of Science ®Google Scholar
• LugaresiARebiSmart™ (version 1.5) device for multiple sclerosis treatment delivery and adherenceExpert Opin Drug Deliv201310227328323252744
   PubMed Web of Science ®Google Scholar
• DevonshireVFeinsteinAFortinKAnxiety and adherence in patients with relapsing multiple sclerosis using RebiSmart for self-injection: preliminary results from the MEASURE studyJ Neurol2012259Suppl 1S111
   PubMed Web of Science ®Google Scholar
• LugaresiABellantonioBBrescia-MorraVBRIDGE: a 12-week, multicentre, open-label, single-arm, Phase IV study of the effect of a new electronic autoinjection device on adherence to subcutaneous interferon beta-1a treatment for relapsing-remitting multiple sclerosisPoster presented at: XLI Congress of the Italian Society of NeurologyOctober 23–27, 2010Catania, Italy
   Google Scholar
• Merck KGaAAn Observational, Retrospective, UK & Ireland Audit of Patient Adherence to Rebif^® Injections Using the RebiSmart™ Injection Device (READER) Available from: http://clinicaltrials.gov/ct2/show/NCT01601080. NLM identifier: NCT01601080Accessed March 7, 2014
   Google Scholar
• PolmanCHReingoldSCBanwellBDiagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteriaAnn Neurol201169229230221387374
   PubMed Web of Science ®Google Scholar
• TreadawayKCutterGSalterAFactors that influence adherence with disease-modifying therapy in MSJ Neurol2009256456857619444532
   PubMed Web of Science ®Google Scholar
• WicksPMassagliMKulkarniADastaniHUse of an online community to develop patient-reported outcome instruments: the Multiple Sclerosis Treatment Adherence Questionnaire (MS-TAQ)J Med Internet Res2011131e1221266318
   PubMed Web of Science ®Google Scholar
• TremlettHLOgerJInterrupted therapy: stopping and switching of the beta-interferons prescribed for MSNeurology200361455155412939437
   PubMed Web of Science ®Google Scholar
• LugaresiAFlorioCBrescia-MorraVBRIDGE study groupPatient adherence to and tolerability of self-administered interferon β-1a using an electronic autoinjection device: a multicentre, open-label, phase IV studyBMC Neurol201212722390218
   PubMed Web of Science ®Google Scholar
• ChengTLOttoliniMCBaumhaftKBrasseuxCWolfMDScheidtPCStrategies to increase adherence with tuberculosis test reading in a high-risk populationPediatrics19971002 Pt 12102139240801
   PubMed Web of Science ®Google Scholar
• HamiltonGATobertsSJJohnsonJMIncreasing adherence in patients with primary hypertension: an interventionHealth Values199317311
   Google Scholar
• RoterDLHallJAMeriscaRNordstromBCretinDSvarstadBEffectiveness of interventions to improve patient compliance: a meta-analysisMed Care1998368113811619708588
   PubMed Web of Science ®Google Scholar
• McDonaldHPGargAXHaynesRBInterventions to enhance patient adherence to medication prescriptions: scientific reviewJAMA2002288222868287912472329
   PubMed Web of Science ®Google Scholar
• MartinLRWilliamsSLHaskardKBDimatteoMRThe challenge of patient adherenceTher Clin Risk Manag20051318919918360559
   PubMedGoogle Scholar
• NauDPProportion of Days Covered (PDC) as a preferred method of measuring medication adherence Available from: http://www.pqaalliance.org/images/uploads/files/PQA%20PDC%20vs%20%20MPR.pdfAccessed December 10, 2013
   Google Scholar
• FreedmanMForrestalFTreatment optimization recommendations can predict relapse rates in patients with MS: analysis of the PRISMS study dataPoster presented at: American Academy of Neurology 57th Annual MeetingApril 9–16, 2005Miami Beach, FL
   Google Scholar
• TruemanPLowsonKBligheAEvaluation of the scale, causes and costs of waste medicines Available from: http://eprints.pharmacy.ac.uk/2605/1/Evaluation_of_NHS_Medicines_Waste__web_publication_version.pdfAccessed December 10, 2013
   Google Scholar
• DevonshireVArbizuTBorreBPatient-rated suitability of a novel electronic device for self-injection of subcutaneous interferon beta-1a in relapsing multiple sclerosis: an international, single-arm, multicentre, Phase IIIb studyBMC Neurol2010102820433746
   PubMed Web of Science ®Google Scholar